Always talk to your doctor about the risks and benefits of any treatment
The authors observed that several endpoints had not reached an apparent plateau by 36 weeks in the higher-dose groups, an observation they noted as informative for phase 3 program design
8,9,30 The agents used in these trials, including higher-dose semaglutide (2.4 mg) and the dual GLP-1/GIP receptor agonist tirzepatide, have demonstrated compelling benefits
Retatrutide is the name clinical researchers cannot stop talking about
YouTube: Diabetes Facts.
She didn't think quitting the drugs would be that big of a deal: She had lost as much as she wanted to, and in her mind, the company's messaging throughout her two years had suggested that, "unless you were a diabetic, there was no need to stay on the GLP-1." But Isherwood told Fortune that within six to eight months, she gained back about 20 pounds as she reverted to old behaviors when stressors arose in her lifea familiar pattern that she'd experienced before
